Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

NCT00038194 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: imatinib mesylate
DRUG: docetaxel

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]